RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > 2020 > 3 > BPCIA Turns 10: Nearly 100 Drugs Become Biologics

BPCIA Turns 10: Nearly 100 Drugs Become Biologics

Posted 23 March 2020 | By Zachary Brennan 

BPCIA Turns 10: Nearly 100 Drugs Become Biologics

The law that opened up the approval pathway for biosimilars, known as the Biologics Price Competition and Innovation Act (BPCIA), turned 10 years old on Monday and nearly 100 drugs officially became biologics under what’s known as the “deemed to be a license” provision of the BPCIA.

As anticipated, the shift for these nearly 100 products will mean insulin and treatments for respiratory distress syndrome, fertility conditions, Cushing’s syndrome, deep vein thrombosis, Gaucher disease and others will be marketed under biologics license applications (BLAs) and see biosimilar competition moving forward.

Last September, FDA listed the products making the transition. And earlier this month, FDA finalized guidance on what this transition means for sponsors of these products. FDA previously released final guidance on the BPCIA provision back in December 2018.

“Today is a milestone for the future of insulin and other important treatments – potentially a new era of proposed biosimilar and interchangeable insulin products. We expect this regulatory transition to enable a vibrant competitive market for transitioning products, ultimately empowering patients by increasing choices and potentially lowering prices of safe, effective, high-quality medications,” FDA’s Center for Drug Evaluation and Research director Janet Woodcock and principal deputy commissioner Amy Abernethy said in a statement.

And while the biosimilar industry once struggled to launch dozens of products, more than 60% of the FDA-approved biosimilars have now launched and really only the biosimilars for Enbrel (etanercept) and Humira (adalimumab) have yet to materialize.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.